Carbon Ion Radiation Therapy for Primary Renal Cell Carcinoma: Initial Clinical Experience

International Journal of Radiation Oncology Biology Physics

Volumn 72, Issue 3, 2008, Pages 828-833

  Nomiya, Takuma ^a   Tsuji, Hiroshi ^a   Hirasawa, Naoki ^a   Kato, Hiroyuki ^a   Kamada, Tadashi ^a   Mizoe, Junetsu ^a   Kishi, Hirohisa ^b   Kamura, Koichi ^c   Wada, Hitoshi ^d   Nemoto, Kenji ^d   Tsujii, Hirohiko ^a  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NARITA RED CROSS HOSPITAL   (Japan)

^c SAKURA NATIONAL HOSPITAL   (Japan)

^d YAMAGATA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Carbon ion radiotherapy; Particle radiotherapy; Renal cell carcinoma; Survival analysis; Tumor response

Indexed keywords

CONCRETE DAMS; ELECTROTHERAPEUTICS; ONCOLOGY; RADIOTHERAPY; SHRINKAGE; STAGES; SURGERY; TOXICITY;

ADDITIONAL TREATMENT; AFTER-TREATMENT; CARBON ION RADIOTHERAPY; CAUSE-SPECIFIC SURVIVAL; CLINICAL EXPERIENCE; CURATIVE RADIOTHERAPY; ION RADIATION; LOCAL CONTROL; LOCAL CONTROLLABILITY; LOCAL RECURRENCE; OVERALL SURVIVAL RATES; PARTICLE RADIOTHERAPY; PROGRESSION-FREE SURVIVAL; RENAL CELL CARCINOMA; SKIN TOXICITY; SURVIVAL ANALYSIS; TOTAL-DOSE; TUMOR RESPONSE;

TUMORS;

ALPHA INTERFERON;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; KIDNEY CARCINOMA; MALE; PRIORITY JOURNAL; RADIATION DOSE FRACTIONATION; SKIN TOXICITY; TUMOR GROWTH;

AGED; AGED, 80 AND OVER; CARBON RADIOISOTOPES; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HUMANS; INCIDENCE; KIDNEY NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; PARTICLE ACCELERATORS; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; UNITED STATES;

EID: 52949099482     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2008.01.043     Document Type: Article

References (25)

1. American Cancer Society. Cancer Facts and Figures 2007 (2007), American Cancer Society, Atlanta, GA
2. Ajiki W., Tsukuma H., and Oshima A. Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1999: Estimates based on data from 11 population-based cancer registries. Jpn J Clin Oncol 34 (2004) 352-356
3. Goetzl M.A., Desai M., Mansukhani M., et al. Natural history and clinical outcome of sporadic renal cortical tumors diagnosed in the young adult. Urology 63 (2004) 41-45
4. Steinbach F., Stockle M., Muller S.C., et al. Conservative surgery of renal cell tumors in 140 patients: 21 Years of experience. J Urol 148 (1992) 24-29
5. Thrasher J.B., Robertson J.E., and Paulson D.F. Expanding indications for conservative renal surgery in renal cell carcinoma. Urology 43 (1994) 160-168
6. Novick A.C. Laparoscopic and partial nephrectomy. Clin Cancer Res 10 (2004) 6322S-6327S
7. Phillips E., and Messing E.M. Role of lymphadenectomy in the treatment of renal cell carcinoma. Urology 41 (1993) 9-15
8. Dutcher J.P., Logan T., Gordon M., et al. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: A Cytokine Working Group study. Clin Cancer Res 6 (2000) 3442-3450
9. Onufrey V., and Mohiuddin M. Radiation therapy in the treatment of metastatic renal cell carcinoma. Int J Radiat Oncol Biol Phys 11 (1985) 2007-2009
10. DiBiase S.J., Valicenti R.K., Schultz D., et al. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: Support for dose escalation based on a biological model. J Urol 158 (1997) 746-749
11. Zink S., Antoine J., and Mahoney F.J. Fast neutron therapy clinical trials in the United States. Am J Clin Oncol 12 (1989) 277-282
12. Wronski M., Maor M.H., Davis B.J., et al. External radiation of brain metastases from renal carcinoma: A retrospective study of 119 patients from the M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 37 (1997) 753-759
13. Suzuki M., Kase Y., Yamaguchi H., et al. Relative biological effectiveness for cell-killing effect on various human cell lines irradiated with Heavy-Ion Medical Accelerator in Chiba (HIMAC) carbon-ion beams. Int J Radiat Oncol Biol Phys 48 (2000) 241-250
14. Kanai T., Matsufuji N., Miyamoto T., et al. Examination of GyE system for HIMAC carbon therapy. Int J Radiat Oncol Biol Phys 64 (2006) 650-656
15. Endo M., Koyama-Ito H., Minohara S., et al. HIPLAN-a heavy ion treatment planning system at HIMAC. J Jpn Soc Ther Radiol Oncol 8 (1996) 231-238
16. Minohara S., Kanai T., Endo M., et al. Respiratory gated irradiation system for heavy-ion radiotherapy. Int J Radiat Oncol Biol Phys 47 (2000) 1097-1103
17. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 80 (1997) 992-993
18. Okunaga T., Matsuo T., Hayashi N., et al. Linear accelerator radiosurgery for vestibular schwannoma: Measuring tumor volume changes on serial three-dimensional spoiled gradient-echo magnetic resonance images. J Neurosurg 103 (2005) 53-58
19. Volpe A., Panzarella T., Rendon R.A., et al. The natural history of incidentally detected small renal masses. Cancer 100 (2004) 738-745
20. Sowery R.D., and Siemens D.R. Growth characteristics of renal cortical tumors in patients managed by watchful waiting. Can J Urol 11 (2004) 2407-2410
21. Kouba E., Smith A., McRackan D., et al. Watchful waiting for solid renal masses: Insight into the natural history and results of delayed intervention. J Urol 177 (2007) 466-470
22. Ozono S., Miyao N., Igarashi T., et al. Japanese Society of Renal Cancer. Tumor doubling time of renal cell carcinoma measured by CT: Collaboration of Japanese Society of Renal Cancer. Jpn J Clin Oncol 34 (2004) 82-85
23. Wersall P.J., Blomgren H., Lax I., et al. Extracranial stereotactic radiotherapy for primary and metastatic renal cell carcinoma. Radiother Oncol 77 (2005) 88-95
24. Kane R.C., Farrell A.T., Saber H., et al. Sorafenib for the treatment of advanced renal cell carcinoma. Clin Cancer Res 12 (2006) 7271-7278
25. Hudes G., Carducci M., Tomczak P., et al. Global ARCC Trial. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356 (2007) 2271-2281